Abstract
4/2025
vol. 12
Guidelines/recommendations
Position statement of the HAE Section of the Polish Society of Allergology on the management of hereditary angioedema due to C1 inhibitor deficiency: 2025 update. Part II: treatment, monitoring, perioperative management, and the particular aspects of care for women and children
- Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Krakow, Poland
- Department of Internal Diseases, Pneumonology, Allergology, Clinical Immunology and Rare Diseases, Military Institute of Medicine – National Research Institute, Warsaw, Poland
- 1st Clinical Department of Pediatrics, Allergology and Cardiology, Wroclaw Medical University, Wroclaw, Poland
- ALERGODERM, Specialist Medical Practice, Bydgoszcz, Poland
- Department of Pediatric Pneumonology and Allergy, Medical University of Warsaw, Poland
- Greater Poland Center of Pulmonology and Thoracic Surgery, Poznan, Poland
- Department of Immunology and Allergy, Central Teaching Hospital of the Medical University of Lodz, Poland
- Department of Pulmonology and Allergology, Faculty of Medicine, Medical University of Gdansk, Poland
- 1st Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Poland
- Independent Public Clinical Hospital No. 2, Pomeranian Medical University, Szczecin, Poland
- Department of Allergology and Lung Diseases, Cardinal Wyszyński Provincial Specialist Hospital SPZOZ, Lublin, Poland
- Department of Allergology, Clinical Immunology and Internal Medicine, University Hospital No. 2, Bydgoszcz, Poland
- Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
Alergologia Polska – Polish Journal of Allergology 2025; 12, 4: 233–249
Online publish date: 2025/11/21
The second part of the updated guidelines focuses on the treatment of hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH), as well as the specific clinical presentation and management of HAE in special populations, particularly women and children. This section also emphasizes the importance of patient education and appropriate disease monitoring throughout the course of therapy. One of the most significant developments in recent years has been the evolution of long-term prophylaxis (LTP). Several new agents have been approved for use, showing high efficacy in reducing the frequency and severity of attacks, while also contributing to the normalization of patients’ daily functioning and quality of life – all with a favorable safety profile. As a result, a growing number of patients are being successfully managed with LTP. Furthermore, this section elaborates on recommendations for short-term prophylaxis and perioperative management. Since the effectiveness and safety of therapy are closely linked to patient adherence, the guidelines also address home treatment protocols, structured monitoring strategies, and the organization of comprehensive patient care in Poland.
Keywords
monitoring, treatment, recommendations, hereditary angioedema, C1 inhibitor deficiency
Coverage in
Integrated with
